DeepMed Research

Interferon beta-1a

Generic Name: Interferon beta-1a

Brand Names: Avonex, Rebif

Drug Type: Biotech

CAS Number: 145258-61-3

Unique Ingredient Identifier: XRO4566Q4R

Background: Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.

Indication: For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Associated Conditions: Relapsing Multiple Sclerosis (RMS)

Clinical Trials

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA

Phase 2

Terminated

Conditions: Preventive Medicine
Multi Organ Failure

Interventions: Drug: Interferon Beta-1A
Drug: Placebo

First Posted Date: 2017-04-19

Last Posted Date: 2021-01-14

Lead Sponsor: Faron Pharmaceuticals Ltd

Target Recruit Count: 40

Registration Number: NCT03119701

Locations: 🇱🇹
Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania
🇫🇮
Central Finland Central Hospital, Jyväskylä, Finland
🇪🇪
Tartu University Hospital, Tartu, Estonia

and more 6 locations

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: Rebif

First Posted Date: 2016-10-31

Last Posted Date: 2019-01-18

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 2

Registration Number: NCT02949908

Locations: 🇩🇪
Please Contact the Merck KGaA Communication Center, Darmstadt, Germany

National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta 1a
Drug: Mitoxantrone

First Posted Date: 2016-10-18

Last Posted Date: 2023-03-29

Lead Sponsor: Rennes University Hospital

Target Recruit Count: 35

Registration Number: NCT02937285

Locations: 🇫🇷
CHU Rennes, Rennes, France

Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Completed

Conditions: Relapsing Multiple Sclerosis (RMS)

Interventions: Drug: Rebif (Interferon beta-1a)

First Posted Date: 2016-09-30

Last Posted Date: 2022-04-04

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 594

Registration Number: NCT02921035

Locations: 🇸🇦
Research site, Riyadh, Saudi Arabia
🇲🇦
Research site 2, Rabat, Morocco
🇲🇦
Research site 3, Rabat, Morocco

and more 1 locations

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Rebif
Drug: Tecfidera

First Posted Date: 2016-07-06

Last Posted Date: 2018-03-01

Lead Sponsor: IMS HEALTH GmbH & Co. OHG

Target Recruit Count: 479

Registration Number: NCT02823951

Locations: 🇺🇸
Savannah Neurology Specialists, Savannah, Georgia, United States
🇺🇸
Northshore University, Evanston, Illinois, United States
🇺🇸
Washington university, Saint Louis, Missouri, United States

and more 20 locations

EPID Multiple Sclerosis Pregnancy Study

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
Other: No MSDMDs therapy (control)
Drug: Extavia (interferon beta-1b), Novartis Pharma AG
Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd
Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd
Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
Drug: Avonex (interferon beta-1a), Biogen Idec Ltd

First Posted Date: 2016-04-25

Last Posted Date: 2019-08-14

Lead Sponsor: Bayer

Target Recruit Count: 2089

Registration Number: NCT02749396

Locations: 🇫🇮
Many locations, Multiple Locations, Finland

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia, Influenza, COVID-19

Interventions: Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Eritoran
Drug: Moxifloxacin or Levofloxacin
Drug: Fixed-duration Hydrocortisone
Drug: Extended course macrolide
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Cysteamine
Drug: Imatinib
Drug: Angiotensin Receptor Blockers
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Intermediate dose thromboprophylaxis
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Fixed-duration dexamethasone
Drug: Amoxicillin-clavulanate
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil

First Posted Date: 2016-04-13

Last Posted Date: 2024-07-12

Lead Sponsor: UMC Utrecht

Target Recruit Count: 20000

Registration Number: NCT02735707

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Rebif (interferon beta 1a)
Drug: Placebo
Drug: BCD-033 (interferon beta 1a)

First Posted Date: 2016-04-05

Last Posted Date: 2023-02-17

Lead Sponsor: Biocad

Target Recruit Count: 163

Registration Number: NCT02727907

Locations: 🇷🇺
Scientific neurology center, RAS, Moscow, Russian Federation

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

Phase 3

Terminated

Conditions: Respiratory Distress Syndrome, Adult

Interventions: Drug: Placebo
Drug: Interferon beta-1a

First Posted Date: 2015-12-04

Last Posted Date: 2020-03-30

Lead Sponsor: Faron Pharmaceuticals Ltd

Target Recruit Count: 301

Registration Number: NCT02622724

Locations: 🇧🇪
Erasmus Hospital, Brussels, Belgium
🇫🇮
Tampere University Hospital, Tampere, Finland
🇫🇷
CHU De Poitiers, Poitiers, Poitou-Charentes, France

and more 68 locations

Phase I BP Interferon (IFN) Beta-001

Phase 1

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Interferon beta-1a

First Posted Date: 2015-08-05

Last Posted Date: 2015-08-06

Lead Sponsor: Centre Hospitalier Universitaire Vaudois

Target Recruit Count: 12

Registration Number: NCT02515695

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy